Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee

Osteoarthritis Clinical Trial

— C-SOUND  

Official title:

A 26-week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Study to Evaluate the Efficacy and Safety of a Single Dose of 6 mL of Hylan G-F 20 (Synvisc-One®) in Chinese Patients With Symptomatic Osteoarthritis of the Knee

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03190369
• Other study ID #: EFC12723
• Secondary ID: U1111-1131-0507
• Status: Completed
• Phase: Phase 3
• Start date: August 21, 2017
• Est. completion date: January 28, 2019

Study information

• Verified date: March 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

-To evaluate the efficacy of a single 6-milliliter (mL) intra-articular (IA) injection of Hylan G-F 20 measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numerical Rating Scale (NRS) 3.1 A1 score, in comparison to an IA placebo injection over 26 weeks, in Chinese participants with symptomatic Osteoarthritis (OA) of the knee.

Secondary Objectives:

• To evaluate the efficacy of a single 6-mL IA injection of Hylan G-F 20 measured by 7-day average score of WOMAC A1 pain sub-score in comparison to an IA placebo injection over 26 weeks.

• To evaluate the efficacy of a single 6-mL IA injection of Hylan G-F 20 measured by WOMAC A, patient global assessment (PTGA) and clinical observer global assessment (COGA) in comparison to an IA placebo injection over 26 weeks.

• To evaluate the response rate of a single 6-mL IA injection of Hylan G-F 20 in comparison to an IA placebo injection over 26 weeks. Response was defined as WOMAC A1 greater than or equal to (>=) 2-point improvement from baseline on NRS.

• To evaluate the safety of a single 6-mL IA injection of Hylan G-F 20, in comparison to an IA placebo injection over 26 weeks.

Description:

The duration of the study was 29 weeks at maximum. The screening and wash-out period lasted for up to 14 days, depending on the half-life of the medications followed by an 8-day baseline period including the treatment day. Overall, there were up to 21 days between signing informed consent (at screening visit) and the randomization (Day 1). Treatment was administered on Day 1, and follow-up period was 26 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 440
• Est. completion date: January 28, 2019
• Est. primary completion date: January 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion criteria :

• Symptomatic OA of the target knee joint with WOMAC A1 NRS score of >=4.0 and less than or equal to (<=) 8.0 as recorded in the baseline period.

• Confirmed by standard X-rays performed within 3 months prior to screening visit:

modified Kellgren-Lawrence Numerical Grading System of Grade I-III in the target knee joint.

• According to the American College of Rheumatology (ACR) Criteria.

• With failure to respond adequately to conservative non-pharmacologic therapy and/or simple analgesics, such as acetaminophen.

• Participant was willing and was able to provide signed informed consent prior to any study related procedures being performed.

Exclusion criteria:

• The score of contralateral knee pain (if present) >3.0 NRS at screening visit.

• Ipsilateral hip OA.

• Participant with systemic corticosteroids within 12 weeks prior to screening visit.

• Participant with injection of IA corticosteroids in the target knee joint within 26 weeks prior to screening visit.

• Concurrent chronic pain conditions with pain score >3.0 NRS at screening, or peripheral or central neuropathy that may affect sensation of the target knee area, including but not limited to back pain, hip pain, disc herniation, sciatica, diabetic neuropathy, post-stroke pain or fibromyalgia.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Device:
• Hylan G-F 20 (GZ402662/SAR402662)
Pharmaceutical form: Solution for injection Route of administration: Intra articular

Drug:
• Placebo
Pharmaceutical form: Solution for injection Route of administration: Intra articular

Locations

Country	Name	City	State
China	Investigational Site Number 1560001	Beijing
China	Investigational Site Number 1560005	Beijing
China	Investigational Site Number 1560009	Beijing
China	Investigational Site Number 1560020	Beijing
China	Investigational Site Number 1560012	Changchun
China	Investigational Site Number 1560013	Changsha
China	Investigational Site Number 1560023	Chengdu
China	Investigational Site Number 1560016	Guangzhou
China	Investigational Site Number 1560011	Hohhot
China	Investigational Site Number 1560017	Kunming
China	Investigational Site Number 1560019	Nanjing
China	Investigational Site Number 1560021	Nanjing
China	Investigational Site Number 1560007	Qingdao
China	Investigational Site Number 1560002	Shanghai
China	Investigational Site Number 1560003	Shanghai
China	Investigational Site Number 1560022	Shanghai
China	Investigational Site Number 1560018	Taiyuan
China	Investigational Site Number 1560010	Tianjin
China	Investigational Site Number 1560015	Tianjin
China	Investigational Site Number 1560006	Wuhan
China	Investigational Site Number 1560008	Wuxi

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 Pain (Walking Pain) Subscale Score Over 26 Weeks	The WOMAC Numerical Rating Scale (NRS) version 3.1 questionnaire was a self-administered, health status measure questionnaire of 24 questions comprising 3 subscales (joint pain, stiffness and physical function) for participants with Osteoarthritis (OA) of the knee. WOMAC A1 pain subscale (measure of pain during walking on a flat surface) was measured on 11-point (NRS) ranging from 0 (none) to 10 (extreme), where lower score represented no pain and higher score represented extreme pain.	From Baseline up to Week 26
Secondary	Change From Baseline in 7-day Average WOMAC A1 Pain (Walking Pain) Subscale Score Over 26 Weeks	The WOMAC NRS version 3.1 questionnaire was a self-administered, health status measure questionnaire of 24 questions comprising 3 subscales (joint pain, stiffness and physical function) for participants with OA of the knee. WOMAC A1 pain subscale (measure of pain during walking on a flat surface) was measured on 11-point (NRS) ranging from 0 (none) to 10 (extreme), where lower score represented no pain and higher score represented extreme pain. For 7-day average WOMAC A1, the baseline value was defined as the average of the WOMAC A1 scores recorded 7 days prior to the first investigational medicinal product (IMP) administration (WOMAC A1 score recorded on Day 1 included). The 7-day average WOMAC A1 was set as missing if 3 or more of the 7 WOMAC A1 scores were missing.	From Baseline up to Week 26
Secondary	Change From Baseline in WOMAC A Score Over 26 Weeks	The WOMAC NRS version 3.1 questionnaire was a self-administered, health status measure questionnaire of 24 questions comprising 3 subscales (joint pain, stiffness and physical function) for participants with OA of the knee. WOMAC A (5 items: measure of pain while walking, using stairs, at night while in bed, sitting or lying, and standing); each item was measured on 11-point (NRS) ranging from 0 (none) to 10 (extreme), where lower score represented no pain and higher score represented extreme pain. Total WOMAC A score was the sum of 5 item scores and ranges from 0 (none) to 50 (extreme); where lower score represented no pain and higher score represented extreme pain.	From Baseline up to Week 26
Secondary	Change From Baseline in Patient Global Self-Assessment (PTGA) Score of Osteoarthritis Over 26 Weeks	PTGA (self-assessment of target knee OA condition) was measured using an 11-point NRS ranging from 0 (best possible) to 10 (worst possible), where lower score represented best possible condition and higher score represented worst possible condition.	From Baseline up to Week 26
Secondary	Change From Baseline in Clinical Observer Global Assessment (COGA) Score of Osteoarthritis Over 26 Weeks	COGA was used by the physicians to perform a global assessment of the participant's target knee OA condition. The response was captured using the 11-point NRS pain intensity rating scale ranging from 0 (best possible) to 10 (worst possible) at the specified time points, where lower score represented best possible condition and higher score represented worst possible condition.	From Baseline up to Week 26
Secondary	Percentage of Positive WOMAC A1 Responder Over 26 Weeks	WOMAC A1 responder were defined as >=2-point improvement from baseline in the WOMAC A1 NRS. The WOMAC NRS version 3.1 questionnaire was a self-administered, health status measure questionnaire of 24 questions comprising 3 subscales (joint pain, stiffness and physical function) for participants with OA of the knee. WOMAC A1 pain subscale (measure of pain during walking on a flat surface) was measured on 11-point (NRS) ranging from 0 (none) to 10 (extreme), where lower score represented no pain and higher score represented extreme pain.	Week 4, Week 8, Week 12, Week 16, Week 20 and Week 26
Secondary	Number of Participants With Treatment Emergent Adverse Events (TEAEs)	Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened (according to the Investigator opinion), or became serious during the on-treatment period (time from the injection of IMP up to Week 26 follow-up visit).	From Baseline up to Week 26